The listening room with a bespoke sound system reflecting Alessandro Michele's vision was conceived in partnership with ...

Similarly, the American College of Physicians advises starting with interventions such as physical therapy ... Copenhaver is a recent speaker for Vertex Pharmaceuticals, Inc. Cohen is anticipated ...

People living with cystic fibrosis can now take a once-daily drug that will help them breathe easier all day long, thanks to ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

Some insurers limit sessions to just 20 a year. They also often pause coverage to require re-authorization of physical ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

The clinical pause is “temporary” and applies to a multiple ascending dose portion of a trial assessing VX-522, a Moderna-partnered mRNA therapy, according to Vertex’s May 5 earnings release.

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

From a new product perspective, Vertex is progressing nicely with Casgevy (a gene therapy treatment for sickle cell disease) securing authorized treatment centers worldwide, including key ...